Tesaro's Varubi: Safety, Dosing Convenience Could Drive Third NK-1 Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval for prevention of chemotherapy induced nausea and vomiting in delayed phase after chemo paves way for fourth-quarter market entry.
You may also be interested in...
US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing
Tesaro’s IV formulation of Varubi draws letter keeping with last year’s emerging trend of manufacturing-related CRLs, in this case agency concerns about CMC data related to comparability of drug produced by two different contractors; issue seems unlikely to significantly delay approval of the new version of CINV drug, however.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.